nodes	percent_of_prediction	percent_of_DWPC	metapath
Riluzole—ABCG2—Fluorouracil—urinary bladder cancer	0.1	0.18	CbGbCtD
Riluzole—ABCG2—Carboplatin—urinary bladder cancer	0.0998	0.179	CbGbCtD
Riluzole—ABCG2—Cisplatin—urinary bladder cancer	0.0853	0.153	CbGbCtD
Riluzole—ABCG2—Etoposide—urinary bladder cancer	0.0838	0.15	CbGbCtD
Riluzole—ABCG2—Doxorubicin—urinary bladder cancer	0.0571	0.102	CbGbCtD
Riluzole—ABCG2—Methotrexate—urinary bladder cancer	0.0554	0.0993	CbGbCtD
Riluzole—CYP1A2—Fluorouracil—urinary bladder cancer	0.0414	0.0742	CbGbCtD
Riluzole—CYP1A2—Etoposide—urinary bladder cancer	0.0345	0.062	CbGbCtD
Riluzole—CYP1A2—urine—urinary bladder cancer	0.00312	0.16	CbGeAlD
Riluzole—SLC7A11—smooth muscle tissue—urinary bladder cancer	0.0025	0.129	CbGeAlD
Riluzole—SLC7A11—renal system—urinary bladder cancer	0.00241	0.124	CbGeAlD
Riluzole—SLC7A11—female reproductive system—urinary bladder cancer	0.00193	0.0992	CbGeAlD
Riluzole—ABCG2—prostate gland—urinary bladder cancer	0.00116	0.0598	CbGeAlD
Riluzole—SCN5A—vagina—urinary bladder cancer	0.00105	0.054	CbGeAlD
Riluzole—ABCG2—seminal vesicle—urinary bladder cancer	0.000985	0.0506	CbGeAlD
Riluzole—CYP1A1—epithelium—urinary bladder cancer	0.000812	0.0417	CbGeAlD
Riluzole—ABCG2—urethra—urinary bladder cancer	0.000779	0.0401	CbGeAlD
Riluzole—CYP1A2—renal system—urinary bladder cancer	0.000764	0.0392	CbGeAlD
Riluzole—CYP1A1—renal system—urinary bladder cancer	0.000753	0.0387	CbGeAlD
Riluzole—CYP1A1—urethra—urinary bladder cancer	0.00074	0.038	CbGeAlD
Riluzole—CYP1A1—female reproductive system—urinary bladder cancer	0.000603	0.031	CbGeAlD
Riluzole—ABCG2—vagina—urinary bladder cancer	0.000575	0.0295	CbGeAlD
Riluzole—CYP1A1—vagina—urinary bladder cancer	0.000546	0.028	CbGeAlD
Riluzole—CYP1A2—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00046	0.00583	CbGpPWpGaD
Riluzole—CYP1A1—Oxidative Stress—GPX1—urinary bladder cancer	0.000459	0.00582	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000456	0.00578	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000444	0.00563	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000444	0.00563	CbGpPWpGaD
Riluzole—ABCG2—HIF-2-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000441	0.00559	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—GSTO2—urinary bladder cancer	0.000438	0.00555	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—NAT1—urinary bladder cancer	0.000438	0.00555	CbGpPWpGaD
Riluzole—CYP1A2—Phase II conjugation—UGT2B7—urinary bladder cancer	0.000437	0.00554	CbGpPWpGaD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000433	0.00549	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000432	0.00548	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000401	0.00509	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—UGT2B7—urinary bladder cancer	0.000401	0.00508	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000395	0.00501	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000384	0.00487	CbGpPWpGaD
Riluzole—ABCG2—lymph node—urinary bladder cancer	0.000372	0.0191	CbGeAlD
Riluzole—CYP1A1—Biological oxidations—CYP4B1—urinary bladder cancer	0.000361	0.00457	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000356	0.00451	CbGpPWpGaD
Riluzole—CYP1A1—lymph node—urinary bladder cancer	0.000353	0.0181	CbGeAlD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000351	0.00446	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—SRC—urinary bladder cancer	0.000343	0.00435	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	0.000332	0.00421	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—CNTN2—urinary bladder cancer	0.000329	0.00417	CbGpPWpGaD
Riluzole—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000329	0.00417	CbGpPWpGaD
Riluzole—CYP1A1—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000305	0.00387	CbGpPWpGaD
Riluzole—ABCG2—HIF-2-alpha transcription factor network—EP300—urinary bladder cancer	0.0003	0.00381	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000295	0.00374	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00029	0.00368	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—KRAS—urinary bladder cancer	0.000284	0.0036	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000283	0.00359	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000283	0.00359	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000279	0.00354	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000279	0.00354	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000275	0.00349	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000267	0.00339	CbGpPWpGaD
Riluzole—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.000262	0.00332	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.00026	0.00329	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000259	0.00329	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.000255	0.00324	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000252	0.00319	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—HRAS—urinary bladder cancer	0.000241	0.00306	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—NAT2—urinary bladder cancer	0.00024	0.00304	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—IFNA2—urinary bladder cancer	0.00024	0.00304	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000237	0.003	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000236	0.003	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000233	0.00296	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.00023	0.00292	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000227	0.00288	CbGpPWpGaD
Riluzole—ABCG2—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.00022	0.00279	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000213	0.0027	CbGpPWpGaD
Riluzole—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000209	0.00265	CbGpPWpGaD
Riluzole—SCN5A—L1CAM interactions—SRC—urinary bladder cancer	0.000208	0.00264	CbGpPWpGaD
Riluzole—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.000203	0.00257	CbGpPWpGaD
Riluzole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000198	0.00251	CbGpPWpGaD
Riluzole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	0.000195	0.00248	CbGpPWpGaD
Riluzole—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000194	0.00247	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000192	0.00243	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—HPGDS—urinary bladder cancer	0.000192	0.00243	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—GSTT1—urinary bladder cancer	0.000186	0.00236	CbGpPWpGaD
Riluzole—SCN5A—L1CAM interactions—EGFR—urinary bladder cancer	0.000183	0.00231	CbGpPWpGaD
Riluzole—CYP1A1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.00018	0.00228	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000178	0.00226	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	0.000177	0.00224	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000171	0.00217	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.00017	0.00216	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—PLAU—urinary bladder cancer	0.00017	0.00216	CbGpPWpGaD
Riluzole—CYP1A1—PPARA activates gene expression—NCOR1—urinary bladder cancer	0.000169	0.00215	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000169	0.00215	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000168	0.00213	CbGpPWpGaD
Riluzole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—NCOR1—urinary bladder cancer	0.000166	0.0021	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.00016	0.00202	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.00016	0.00202	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000155	0.00197	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000155	0.00197	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000153	0.00194	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000151	0.00191	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000149	0.00189	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000145	0.00184	CbGpPWpGaD
Riluzole—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000141	0.00178	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—CREBBP—urinary bladder cancer	0.00014	0.00178	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000139	0.00177	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000139	0.00176	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—IGF1—urinary bladder cancer	0.000139	0.00176	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000138	0.00176	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000136	0.00173	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000136	0.00173	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.00013	0.00164	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.00013	0.00164	CbGpPWpGaD
Riluzole—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000129	0.00164	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—GSTP1—urinary bladder cancer	0.000129	0.00164	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000129	0.00163	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000127	0.00161	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—RHOA—urinary bladder cancer	0.000127	0.00161	CbGpPWpGaD
Riluzole—Sweating—Doxorubicin—urinary bladder cancer	0.000127	0.000368	CcSEcCtD
Riluzole—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000127	0.000368	CcSEcCtD
Riluzole—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000126	0.000367	CcSEcCtD
Riluzole—Haematuria—Doxorubicin—urinary bladder cancer	0.000126	0.000366	CcSEcCtD
Riluzole—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000126	0.000366	CcSEcCtD
Riluzole—Urethral disorder—Epirubicin—urinary bladder cancer	0.000126	0.000365	CcSEcCtD
Riluzole—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000125	0.000363	CcSEcCtD
Riluzole—Epistaxis—Doxorubicin—urinary bladder cancer	0.000125	0.000362	CcSEcCtD
Riluzole—Angiopathy—Methotrexate—urinary bladder cancer	0.000124	0.000361	CcSEcCtD
Riluzole—Sinusitis—Doxorubicin—urinary bladder cancer	0.000124	0.00036	CcSEcCtD
Riluzole—Immune system disorder—Methotrexate—urinary bladder cancer	0.000124	0.00036	CcSEcCtD
Riluzole—Dizziness—Fluorouracil—urinary bladder cancer	0.000124	0.00036	CcSEcCtD
Riluzole—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000124	0.000359	CcSEcCtD
Riluzole—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000123	0.000359	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—NCOR1—urinary bladder cancer	0.000123	0.00156	CbGpPWpGaD
Riluzole—Chills—Methotrexate—urinary bladder cancer	0.000123	0.000357	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000122	0.00155	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000122	0.00155	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000122	0.00154	CbGpPWpGaD
Riluzole—CYP1A1—PPARA activates gene expression—PPARG—urinary bladder cancer	0.000121	0.00154	CbGpPWpGaD
Riluzole—Diarrhoea—Cisplatin—urinary bladder cancer	0.000121	0.000353	CcSEcCtD
Riluzole—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000121	0.000352	CcSEcCtD
Riluzole—Alopecia—Methotrexate—urinary bladder cancer	0.000121	0.000352	CcSEcCtD
Riluzole—Vomiting—Gemcitabine—urinary bladder cancer	0.000121	0.000352	CcSEcCtD
Riluzole—Bradycardia—Doxorubicin—urinary bladder cancer	0.000121	0.000351	CcSEcCtD
Riluzole—Mental disorder—Methotrexate—urinary bladder cancer	0.00012	0.000349	CcSEcCtD
Riluzole—Rash—Gemcitabine—urinary bladder cancer	0.00012	0.000349	CcSEcCtD
Riluzole—Dermatitis—Gemcitabine—urinary bladder cancer	0.00012	0.000349	CcSEcCtD
Riluzole—Eye disorder—Epirubicin—urinary bladder cancer	0.00012	0.000348	CcSEcCtD
Riluzole—Hypersensitivity—Etoposide—urinary bladder cancer	0.00012	0.000348	CcSEcCtD
Riluzole—Malnutrition—Methotrexate—urinary bladder cancer	0.000119	0.000347	CcSEcCtD
Riluzole—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000119	0.000347	CcSEcCtD
Riluzole—Headache—Gemcitabine—urinary bladder cancer	0.000119	0.000347	CcSEcCtD
Riluzole—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000119	0.000346	CcSEcCtD
Riluzole—Vomiting—Fluorouracil—urinary bladder cancer	0.000119	0.000346	CcSEcCtD
Riluzole—Rhinitis—Doxorubicin—urinary bladder cancer	0.000119	0.000346	CcSEcCtD
Riluzole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—urinary bladder cancer	0.000119	0.00151	CbGpPWpGaD
Riluzole—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000119	0.000345	CcSEcCtD
Riluzole—Hepatitis—Doxorubicin—urinary bladder cancer	0.000119	0.000345	CcSEcCtD
Riluzole—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000119	0.0015	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000119	0.0015	CbGpPWpGaD
Riluzole—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000118	0.000343	CcSEcCtD
Riluzole—Rash—Fluorouracil—urinary bladder cancer	0.000118	0.000343	CcSEcCtD
Riluzole—Dermatitis—Fluorouracil—urinary bladder cancer	0.000118	0.000343	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000118	0.00149	CbGpPWpGaD
Riluzole—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000118	0.000342	CcSEcCtD
Riluzole—Headache—Fluorouracil—urinary bladder cancer	0.000117	0.000341	CcSEcCtD
Riluzole—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000117	0.000341	CcSEcCtD
Riluzole—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000117	0.00034	CcSEcCtD
Riluzole—CYP1A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000117	0.00148	CbGpPWpGaD
Riluzole—Dysgeusia—Methotrexate—urinary bladder cancer	0.000117	0.00034	CcSEcCtD
Riluzole—ABCG2—Metabolism—GSTZ1—urinary bladder cancer	0.000117	0.00148	CbGpPWpGaD
Riluzole—CYP1A1—PPARA activates gene expression—CREBBP—urinary bladder cancer	0.000117	0.00148	CbGpPWpGaD
Riluzole—Asthenia—Etoposide—urinary bladder cancer	0.000117	0.000339	CcSEcCtD
Riluzole—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000117	0.000339	CcSEcCtD
Riluzole—Angiopathy—Epirubicin—urinary bladder cancer	0.000116	0.000338	CcSEcCtD
Riluzole—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000116	0.000338	CcSEcCtD
Riluzole—Immune system disorder—Epirubicin—urinary bladder cancer	0.000116	0.000337	CcSEcCtD
Riluzole—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000116	0.000336	CcSEcCtD
Riluzole—Back pain—Methotrexate—urinary bladder cancer	0.000115	0.000335	CcSEcCtD
Riluzole—Chills—Epirubicin—urinary bladder cancer	0.000115	0.000334	CcSEcCtD
Riluzole—Pruritus—Etoposide—urinary bladder cancer	0.000115	0.000334	CcSEcCtD
Riluzole—Arrhythmia—Epirubicin—urinary bladder cancer	0.000115	0.000333	CcSEcCtD
Riluzole—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000114	0.00145	CbGpPWpGaD
Riluzole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—NCOR1—urinary bladder cancer	0.000114	0.00145	CbGpPWpGaD
Riluzole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—urinary bladder cancer	0.000114	0.00145	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000113	0.00144	CbGpPWpGaD
Riluzole—Alopecia—Epirubicin—urinary bladder cancer	0.000113	0.000329	CcSEcCtD
Riluzole—Nausea—Gemcitabine—urinary bladder cancer	0.000113	0.000329	CcSEcCtD
Riluzole—Vomiting—Cisplatin—urinary bladder cancer	0.000113	0.000328	CcSEcCtD
Riluzole—Mental disorder—Epirubicin—urinary bladder cancer	0.000112	0.000327	CcSEcCtD
Riluzole—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000112	0.000326	CcSEcCtD
Riluzole—Rash—Cisplatin—urinary bladder cancer	0.000112	0.000325	CcSEcCtD
Riluzole—Dermatitis—Cisplatin—urinary bladder cancer	0.000112	0.000325	CcSEcCtD
Riluzole—Malnutrition—Epirubicin—urinary bladder cancer	0.000112	0.000325	CcSEcCtD
Riluzole—Diarrhoea—Etoposide—urinary bladder cancer	0.000111	0.000323	CcSEcCtD
Riluzole—Nausea—Fluorouracil—urinary bladder cancer	0.000111	0.000323	CcSEcCtD
Riluzole—Eye disorder—Doxorubicin—urinary bladder cancer	0.000111	0.000322	CcSEcCtD
Riluzole—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000111	0.000322	CcSEcCtD
Riluzole—ABCG2—Metabolism—GSTO2—urinary bladder cancer	0.000111	0.0014	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—NAT1—urinary bladder cancer	0.000111	0.0014	CbGpPWpGaD
Riluzole—Anaemia—Methotrexate—urinary bladder cancer	0.00011	0.000321	CcSEcCtD
Riluzole—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00011	0.00032	CcSEcCtD
Riluzole—Flatulence—Epirubicin—urinary bladder cancer	0.00011	0.00032	CcSEcCtD
Riluzole—Tension—Epirubicin—urinary bladder cancer	0.00011	0.000318	CcSEcCtD
Riluzole—Dysgeusia—Epirubicin—urinary bladder cancer	0.000109	0.000318	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000109	0.00139	CbGpPWpGaD
Riluzole—Nervousness—Epirubicin—urinary bladder cancer	0.000108	0.000315	CcSEcCtD
Riluzole—Back pain—Epirubicin—urinary bladder cancer	0.000108	0.000314	CcSEcCtD
Riluzole—Angiopathy—Doxorubicin—urinary bladder cancer	0.000108	0.000313	CcSEcCtD
Riluzole—Malaise—Methotrexate—urinary bladder cancer	0.000108	0.000313	CcSEcCtD
Riluzole—Dizziness—Etoposide—urinary bladder cancer	0.000108	0.000312	CcSEcCtD
Riluzole—SCN5A—Axon guidance—RHOA—urinary bladder cancer	0.000107	0.00136	CbGpPWpGaD
Riluzole—Muscle spasms—Epirubicin—urinary bladder cancer	0.000107	0.000312	CcSEcCtD
Riluzole—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000107	0.000312	CcSEcCtD
Riluzole—Vertigo—Methotrexate—urinary bladder cancer	0.000107	0.000312	CcSEcCtD
Riluzole—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000107	0.000311	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000107	0.00136	CbGpPWpGaD
Riluzole—Leukopenia—Methotrexate—urinary bladder cancer	0.000107	0.00031	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—IL2—urinary bladder cancer	0.000107	0.00135	CbGpPWpGaD
Riluzole—Chills—Doxorubicin—urinary bladder cancer	0.000106	0.00031	CcSEcCtD
Riluzole—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000106	0.000308	CcSEcCtD
Riluzole—Nausea—Cisplatin—urinary bladder cancer	0.000105	0.000306	CcSEcCtD
Riluzole—Alopecia—Doxorubicin—urinary bladder cancer	0.000105	0.000305	CcSEcCtD
Riluzole—Cough—Methotrexate—urinary bladder cancer	0.000104	0.000303	CcSEcCtD
Riluzole—Mental disorder—Doxorubicin—urinary bladder cancer	0.000104	0.000302	CcSEcCtD
Riluzole—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000104	0.000301	CcSEcCtD
Riluzole—Convulsion—Methotrexate—urinary bladder cancer	0.000103	0.0003	CcSEcCtD
Riluzole—Vomiting—Etoposide—urinary bladder cancer	0.000103	0.0003	CcSEcCtD
Riluzole—Malnutrition—Doxorubicin—urinary bladder cancer	0.000103	0.0003	CcSEcCtD
Riluzole—Anaemia—Epirubicin—urinary bladder cancer	0.000103	0.0003	CcSEcCtD
Riluzole—Agitation—Epirubicin—urinary bladder cancer	0.000103	0.000298	CcSEcCtD
Riluzole—Rash—Etoposide—urinary bladder cancer	0.000103	0.000298	CcSEcCtD
Riluzole—Dermatitis—Etoposide—urinary bladder cancer	0.000102	0.000298	CcSEcCtD
Riluzole—Headache—Etoposide—urinary bladder cancer	0.000102	0.000296	CcSEcCtD
Riluzole—Flatulence—Doxorubicin—urinary bladder cancer	0.000102	0.000296	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000102	0.00129	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000102	0.00129	CbGpPWpGaD
Riluzole—Myalgia—Methotrexate—urinary bladder cancer	0.000102	0.000295	CcSEcCtD
Riluzole—Chest pain—Methotrexate—urinary bladder cancer	0.000102	0.000295	CcSEcCtD
Riluzole—Arthralgia—Methotrexate—urinary bladder cancer	0.000102	0.000295	CcSEcCtD
Riluzole—Tension—Doxorubicin—urinary bladder cancer	0.000101	0.000295	CcSEcCtD
Riluzole—ABCG2—Metabolism—UGT2B7—urinary bladder cancer	0.000101	0.00128	CbGpPWpGaD
Riluzole—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000101	0.000294	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000101	0.000293	CcSEcCtD
Riluzole—Malaise—Epirubicin—urinary bladder cancer	0.000101	0.000293	CcSEcCtD
Riluzole—Discomfort—Methotrexate—urinary bladder cancer	0.0001	0.000292	CcSEcCtD
Riluzole—Nervousness—Doxorubicin—urinary bladder cancer	0.0001	0.000292	CcSEcCtD
Riluzole—Vertigo—Epirubicin—urinary bladder cancer	0.0001	0.000292	CcSEcCtD
Riluzole—Syncope—Epirubicin—urinary bladder cancer	0.0001	0.000291	CcSEcCtD
Riluzole—Leukopenia—Epirubicin—urinary bladder cancer	0.0001	0.00029	CcSEcCtD
Riluzole—Back pain—Doxorubicin—urinary bladder cancer	9.99e-05	0.00029	CcSEcCtD
Riluzole—SCN5A—Axon guidance—ERBB2—urinary bladder cancer	9.95e-05	0.00126	CbGpPWpGaD
Riluzole—Muscle spasms—Doxorubicin—urinary bladder cancer	9.93e-05	0.000289	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	9.9e-05	0.00125	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	9.9e-05	0.00125	CbGpPWpGaD
Riluzole—Palpitations—Epirubicin—urinary bladder cancer	9.87e-05	0.000287	CcSEcCtD
Riluzole—Confusional state—Methotrexate—urinary bladder cancer	9.82e-05	0.000285	CcSEcCtD
Riluzole—Loss of consciousness—Epirubicin—urinary bladder cancer	9.81e-05	0.000285	CcSEcCtD
Riluzole—Cough—Epirubicin—urinary bladder cancer	9.74e-05	0.000283	CcSEcCtD
Riluzole—Anaphylactic shock—Methotrexate—urinary bladder cancer	9.74e-05	0.000283	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—CDK4—urinary bladder cancer	9.71e-05	0.00123	CbGpPWpGaD
Riluzole—Convulsion—Epirubicin—urinary bladder cancer	9.67e-05	0.000281	CcSEcCtD
Riluzole—Infection—Methotrexate—urinary bladder cancer	9.67e-05	0.000281	CcSEcCtD
Riluzole—Nausea—Etoposide—urinary bladder cancer	9.66e-05	0.000281	CcSEcCtD
Riluzole—Hypertension—Epirubicin—urinary bladder cancer	9.64e-05	0.00028	CcSEcCtD
Riluzole—Ill-defined disorder—Doxorubicin—urinary bladder cancer	9.59e-05	0.000279	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—EP300—urinary bladder cancer	9.56e-05	0.00121	CbGpPWpGaD
Riluzole—Nervous system disorder—Methotrexate—urinary bladder cancer	9.55e-05	0.000278	CcSEcCtD
Riluzole—Anaemia—Doxorubicin—urinary bladder cancer	9.55e-05	0.000278	CcSEcCtD
Riluzole—Thrombocytopenia—Methotrexate—urinary bladder cancer	9.53e-05	0.000277	CcSEcCtD
Riluzole—Chest pain—Epirubicin—urinary bladder cancer	9.51e-05	0.000276	CcSEcCtD
Riluzole—Myalgia—Epirubicin—urinary bladder cancer	9.51e-05	0.000276	CcSEcCtD
Riluzole—Arthralgia—Epirubicin—urinary bladder cancer	9.51e-05	0.000276	CcSEcCtD
Riluzole—Agitation—Doxorubicin—urinary bladder cancer	9.49e-05	0.000276	CcSEcCtD
Riluzole—Anxiety—Epirubicin—urinary bladder cancer	9.47e-05	0.000275	CcSEcCtD
Riluzole—Skin disorder—Methotrexate—urinary bladder cancer	9.46e-05	0.000275	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	9.44e-05	0.000274	CcSEcCtD
Riluzole—Hyperhidrosis—Methotrexate—urinary bladder cancer	9.41e-05	0.000274	CcSEcCtD
Riluzole—ABCG2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	9.4e-05	0.00119	CbGpPWpGaD
Riluzole—Discomfort—Epirubicin—urinary bladder cancer	9.39e-05	0.000273	CcSEcCtD
Riluzole—Malaise—Doxorubicin—urinary bladder cancer	9.32e-05	0.000271	CcSEcCtD
Riluzole—Dry mouth—Epirubicin—urinary bladder cancer	9.3e-05	0.00027	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—SRC—urinary bladder cancer	9.3e-05	0.00118	CbGpPWpGaD
Riluzole—Vertigo—Doxorubicin—urinary bladder cancer	9.28e-05	0.00027	CcSEcCtD
Riluzole—Anorexia—Methotrexate—urinary bladder cancer	9.28e-05	0.00027	CcSEcCtD
Riluzole—Syncope—Doxorubicin—urinary bladder cancer	9.27e-05	0.000269	CcSEcCtD
Riluzole—Leukopenia—Doxorubicin—urinary bladder cancer	9.25e-05	0.000269	CcSEcCtD
Riluzole—Confusional state—Epirubicin—urinary bladder cancer	9.19e-05	0.000267	CcSEcCtD
Riluzole—Palpitations—Doxorubicin—urinary bladder cancer	9.13e-05	0.000265	CcSEcCtD
Riluzole—Oedema—Epirubicin—urinary bladder cancer	9.11e-05	0.000265	CcSEcCtD
Riluzole—Anaphylactic shock—Epirubicin—urinary bladder cancer	9.11e-05	0.000265	CcSEcCtD
Riluzole—ABCG2—Metabolism—CYP4B1—urinary bladder cancer	9.11e-05	0.00116	CbGpPWpGaD
Riluzole—Hypotension—Methotrexate—urinary bladder cancer	9.1e-05	0.000264	CcSEcCtD
Riluzole—Loss of consciousness—Doxorubicin—urinary bladder cancer	9.08e-05	0.000264	CcSEcCtD
Riluzole—Infection—Epirubicin—urinary bladder cancer	9.05e-05	0.000263	CcSEcCtD
Riluzole—Cough—Doxorubicin—urinary bladder cancer	9.02e-05	0.000262	CcSEcCtD
Riluzole—Shock—Epirubicin—urinary bladder cancer	8.97e-05	0.000261	CcSEcCtD
Riluzole—Convulsion—Doxorubicin—urinary bladder cancer	8.95e-05	0.00026	CcSEcCtD
Riluzole—Nervous system disorder—Epirubicin—urinary bladder cancer	8.94e-05	0.00026	CcSEcCtD
Riluzole—Thrombocytopenia—Epirubicin—urinary bladder cancer	8.92e-05	0.000259	CcSEcCtD
Riluzole—Hypertension—Doxorubicin—urinary bladder cancer	8.92e-05	0.000259	CcSEcCtD
Riluzole—Tachycardia—Epirubicin—urinary bladder cancer	8.89e-05	0.000258	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	8.87e-05	0.000258	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	8.87e-05	0.00112	CbGpPWpGaD
Riluzole—Skin disorder—Epirubicin—urinary bladder cancer	8.85e-05	0.000257	CcSEcCtD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	8.83e-05	0.00112	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—PPARG—urinary bladder cancer	8.83e-05	0.00112	CbGpPWpGaD
Riluzole—Hyperhidrosis—Epirubicin—urinary bladder cancer	8.81e-05	0.000256	CcSEcCtD
Riluzole—Insomnia—Methotrexate—urinary bladder cancer	8.81e-05	0.000256	CcSEcCtD
Riluzole—Arthralgia—Doxorubicin—urinary bladder cancer	8.8e-05	0.000256	CcSEcCtD
Riluzole—Chest pain—Doxorubicin—urinary bladder cancer	8.8e-05	0.000256	CcSEcCtD
Riluzole—Myalgia—Doxorubicin—urinary bladder cancer	8.8e-05	0.000256	CcSEcCtD
Riluzole—Anxiety—Doxorubicin—urinary bladder cancer	8.77e-05	0.000255	CcSEcCtD
Riluzole—Paraesthesia—Methotrexate—urinary bladder cancer	8.74e-05	0.000254	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	8.74e-05	0.000254	CcSEcCtD
Riluzole—Discomfort—Doxorubicin—urinary bladder cancer	8.69e-05	0.000253	CcSEcCtD
Riluzole—Anorexia—Epirubicin—urinary bladder cancer	8.69e-05	0.000252	CcSEcCtD
Riluzole—Dyspnoea—Methotrexate—urinary bladder cancer	8.68e-05	0.000252	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	8.67e-05	0.0011	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	8.67e-05	0.0011	CbGpPWpGaD
Riluzole—Somnolence—Methotrexate—urinary bladder cancer	8.66e-05	0.000252	CcSEcCtD
Riluzole—ABCG2—Metabolism—SLC19A1—urinary bladder cancer	8.6e-05	0.00109	CbGpPWpGaD
Riluzole—Dry mouth—Doxorubicin—urinary bladder cancer	8.6e-05	0.00025	CcSEcCtD
Riluzole—Dyspepsia—Methotrexate—urinary bladder cancer	8.57e-05	0.000249	CcSEcCtD
Riluzole—SCN5A—Axon guidance—MMP9—urinary bladder cancer	8.53e-05	0.00108	CbGpPWpGaD
Riluzole—Hypotension—Epirubicin—urinary bladder cancer	8.52e-05	0.000247	CcSEcCtD
Riluzole—Confusional state—Doxorubicin—urinary bladder cancer	8.5e-05	0.000247	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—CREBBP—urinary bladder cancer	8.48e-05	0.00108	CbGpPWpGaD
Riluzole—Decreased appetite—Methotrexate—urinary bladder cancer	8.47e-05	0.000246	CcSEcCtD
Riluzole—Oedema—Doxorubicin—urinary bladder cancer	8.43e-05	0.000245	CcSEcCtD
Riluzole—Anaphylactic shock—Doxorubicin—urinary bladder cancer	8.43e-05	0.000245	CcSEcCtD
Riluzole—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	8.41e-05	0.000244	CcSEcCtD
Riluzole—Fatigue—Methotrexate—urinary bladder cancer	8.4e-05	0.000244	CcSEcCtD
Riluzole—ABCG2—Metabolism—PRSS3—urinary bladder cancer	8.38e-05	0.00106	CbGpPWpGaD
Riluzole—Infection—Doxorubicin—urinary bladder cancer	8.38e-05	0.000243	CcSEcCtD
Riluzole—Pain—Methotrexate—urinary bladder cancer	8.33e-05	0.000242	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	8.3e-05	0.000241	CcSEcCtD
Riluzole—Shock—Doxorubicin—urinary bladder cancer	8.3e-05	0.000241	CcSEcCtD
Riluzole—Nervous system disorder—Doxorubicin—urinary bladder cancer	8.27e-05	0.00024	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	8.26e-05	0.00105	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	8.26e-05	0.00105	CbGpPWpGaD
Riluzole—Thrombocytopenia—Doxorubicin—urinary bladder cancer	8.26e-05	0.00024	CcSEcCtD
Riluzole—Insomnia—Epirubicin—urinary bladder cancer	8.24e-05	0.00024	CcSEcCtD
Riluzole—Tachycardia—Doxorubicin—urinary bladder cancer	8.23e-05	0.000239	CcSEcCtD
Riluzole—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	8.22e-05	0.00104	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	8.19e-05	0.00104	CbGpPWpGaD
Riluzole—Skin disorder—Doxorubicin—urinary bladder cancer	8.19e-05	0.000238	CcSEcCtD
Riluzole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	8.19e-05	0.00104	CbGpPWpGaD
Riluzole—Paraesthesia—Epirubicin—urinary bladder cancer	8.18e-05	0.000238	CcSEcCtD
Riluzole—Hyperhidrosis—Doxorubicin—urinary bladder cancer	8.15e-05	0.000237	CcSEcCtD
Riluzole—Dyspnoea—Epirubicin—urinary bladder cancer	8.12e-05	0.000236	CcSEcCtD
Riluzole—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.11e-05	0.00103	CbGpPWpGaD
Riluzole—Somnolence—Epirubicin—urinary bladder cancer	8.1e-05	0.000235	CcSEcCtD
Riluzole—Anorexia—Doxorubicin—urinary bladder cancer	8.04e-05	0.000234	CcSEcCtD
Riluzole—Feeling abnormal—Methotrexate—urinary bladder cancer	8.02e-05	0.000233	CcSEcCtD
Riluzole—Dyspepsia—Epirubicin—urinary bladder cancer	8.02e-05	0.000233	CcSEcCtD
Riluzole—Gastrointestinal pain—Methotrexate—urinary bladder cancer	7.96e-05	0.000231	CcSEcCtD
Riluzole—CYP1A1—PPARA activates gene expression—EP300—urinary bladder cancer	7.95e-05	0.00101	CbGpPWpGaD
Riluzole—Decreased appetite—Epirubicin—urinary bladder cancer	7.92e-05	0.00023	CcSEcCtD
Riluzole—CYP1A1—Metabolism—GSTZ1—urinary bladder cancer	7.9e-05	0.001	CbGpPWpGaD
Riluzole—Hypotension—Doxorubicin—urinary bladder cancer	7.88e-05	0.000229	CcSEcCtD
Riluzole—SCN5A—Axon guidance—SRC—urinary bladder cancer	7.87e-05	0.000998	CbGpPWpGaD
Riluzole—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	7.87e-05	0.000229	CcSEcCtD
Riluzole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	7.87e-05	0.000998	CbGpPWpGaD
Riluzole—Fatigue—Epirubicin—urinary bladder cancer	7.86e-05	0.000228	CcSEcCtD
Riluzole—Constipation—Epirubicin—urinary bladder cancer	7.79e-05	0.000226	CcSEcCtD
Riluzole—Pain—Epirubicin—urinary bladder cancer	7.79e-05	0.000226	CcSEcCtD
Riluzole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	7.78e-05	0.000986	CbGpPWpGaD
Riluzole—Urticaria—Methotrexate—urinary bladder cancer	7.74e-05	0.000225	CcSEcCtD
Riluzole—Body temperature increased—Methotrexate—urinary bladder cancer	7.7e-05	0.000224	CcSEcCtD
Riluzole—Abdominal pain—Methotrexate—urinary bladder cancer	7.7e-05	0.000224	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—KRAS—urinary bladder cancer	7.7e-05	0.000976	CbGpPWpGaD
Riluzole—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	7.68e-05	0.000223	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—RHOA—urinary bladder cancer	7.67e-05	0.000973	CbGpPWpGaD
Riluzole—Insomnia—Doxorubicin—urinary bladder cancer	7.63e-05	0.000222	CcSEcCtD
Riluzole—Paraesthesia—Doxorubicin—urinary bladder cancer	7.57e-05	0.00022	CcSEcCtD
Riluzole—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	7.56e-05	0.000958	CbGpPWpGaD
Riluzole—Dyspnoea—Doxorubicin—urinary bladder cancer	7.52e-05	0.000218	CcSEcCtD
Riluzole—Feeling abnormal—Epirubicin—urinary bladder cancer	7.51e-05	0.000218	CcSEcCtD
Riluzole—Somnolence—Doxorubicin—urinary bladder cancer	7.5e-05	0.000218	CcSEcCtD
Riluzole—CYP1A1—Metabolism—NAT1—urinary bladder cancer	7.49e-05	0.00095	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GSTO2—urinary bladder cancer	7.49e-05	0.00095	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.45e-05	0.000945	CbGpPWpGaD
Riluzole—Gastrointestinal pain—Epirubicin—urinary bladder cancer	7.45e-05	0.000217	CcSEcCtD
Riluzole—Dyspepsia—Doxorubicin—urinary bladder cancer	7.42e-05	0.000216	CcSEcCtD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.37e-05	0.000934	CbGpPWpGaD
Riluzole—Decreased appetite—Doxorubicin—urinary bladder cancer	7.33e-05	0.000213	CcSEcCtD
Riluzole—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	7.28e-05	0.000212	CcSEcCtD
Riluzole—Fatigue—Doxorubicin—urinary bladder cancer	7.27e-05	0.000211	CcSEcCtD
Riluzole—Urticaria—Epirubicin—urinary bladder cancer	7.24e-05	0.00021	CcSEcCtD
Riluzole—Pain—Doxorubicin—urinary bladder cancer	7.21e-05	0.00021	CcSEcCtD
Riluzole—Constipation—Doxorubicin—urinary bladder cancer	7.21e-05	0.00021	CcSEcCtD
Riluzole—Abdominal pain—Epirubicin—urinary bladder cancer	7.2e-05	0.000209	CcSEcCtD
Riluzole—Body temperature increased—Epirubicin—urinary bladder cancer	7.2e-05	0.000209	CcSEcCtD
Riluzole—Hypersensitivity—Methotrexate—urinary bladder cancer	7.17e-05	0.000209	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—ERBB2—urinary bladder cancer	7.1e-05	0.0009	CbGpPWpGaD
Riluzole—Asthenia—Methotrexate—urinary bladder cancer	6.99e-05	0.000203	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	6.96e-05	0.000883	CbGpPWpGaD
Riluzole—Feeling abnormal—Doxorubicin—urinary bladder cancer	6.95e-05	0.000202	CcSEcCtD
Riluzole—SCN5A—Axon guidance—EGFR—urinary bladder cancer	6.9e-05	0.000875	CbGpPWpGaD
Riluzole—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	6.9e-05	0.0002	CcSEcCtD
Riluzole—Pruritus—Methotrexate—urinary bladder cancer	6.89e-05	0.0002	CcSEcCtD
Riluzole—CYP1A1—Metabolism—UGT2B7—urinary bladder cancer	6.85e-05	0.000869	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—TP53—urinary bladder cancer	6.84e-05	0.000868	CbGpPWpGaD
Riluzole—Hypersensitivity—Epirubicin—urinary bladder cancer	6.71e-05	0.000195	CcSEcCtD
Riluzole—ABCG2—Metabolism—TYMP—urinary bladder cancer	6.7e-05	0.00085	CbGpPWpGaD
Riluzole—Urticaria—Doxorubicin—urinary bladder cancer	6.7e-05	0.000195	CcSEcCtD
Riluzole—Abdominal pain—Doxorubicin—urinary bladder cancer	6.67e-05	0.000194	CcSEcCtD
Riluzole—Body temperature increased—Doxorubicin—urinary bladder cancer	6.67e-05	0.000194	CcSEcCtD
Riluzole—Diarrhoea—Methotrexate—urinary bladder cancer	6.66e-05	0.000194	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—HRAS—urinary bladder cancer	6.54e-05	0.00083	CbGpPWpGaD
Riluzole—Asthenia—Epirubicin—urinary bladder cancer	6.54e-05	0.00019	CcSEcCtD
Riluzole—SCN5A—Axon guidance—KRAS—urinary bladder cancer	6.52e-05	0.000826	CbGpPWpGaD
Riluzole—Pruritus—Epirubicin—urinary bladder cancer	6.45e-05	0.000187	CcSEcCtD
Riluzole—Dizziness—Methotrexate—urinary bladder cancer	6.44e-05	0.000187	CcSEcCtD
Riluzole—Diarrhoea—Epirubicin—urinary bladder cancer	6.24e-05	0.000181	CcSEcCtD
Riluzole—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.21e-05	0.000181	CcSEcCtD
Riluzole—Vomiting—Methotrexate—urinary bladder cancer	6.19e-05	0.00018	CcSEcCtD
Riluzole—CYP1A1—Metabolism—CYP4B1—urinary bladder cancer	6.17e-05	0.000782	CbGpPWpGaD
Riluzole—Rash—Methotrexate—urinary bladder cancer	6.14e-05	0.000178	CcSEcCtD
Riluzole—Dermatitis—Methotrexate—urinary bladder cancer	6.13e-05	0.000178	CcSEcCtD
Riluzole—Headache—Methotrexate—urinary bladder cancer	6.1e-05	0.000177	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—MMP9—urinary bladder cancer	6.09e-05	0.000772	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—NAT2—urinary bladder cancer	6.06e-05	0.000769	CbGpPWpGaD
Riluzole—Asthenia—Doxorubicin—urinary bladder cancer	6.05e-05	0.000176	CcSEcCtD
Riluzole—Dizziness—Epirubicin—urinary bladder cancer	6.03e-05	0.000175	CcSEcCtD
Riluzole—Pruritus—Doxorubicin—urinary bladder cancer	5.97e-05	0.000173	CcSEcCtD
Riluzole—CYP1A1—Metabolism—SLC19A1—urinary bladder cancer	5.82e-05	0.000739	CbGpPWpGaD
Riluzole—Vomiting—Epirubicin—urinary bladder cancer	5.79e-05	0.000168	CcSEcCtD
Riluzole—Nausea—Methotrexate—urinary bladder cancer	5.78e-05	0.000168	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—EP300—urinary bladder cancer	5.77e-05	0.000732	CbGpPWpGaD
Riluzole—Diarrhoea—Doxorubicin—urinary bladder cancer	5.77e-05	0.000168	CcSEcCtD
Riluzole—Rash—Epirubicin—urinary bladder cancer	5.75e-05	0.000167	CcSEcCtD
Riluzole—Dermatitis—Epirubicin—urinary bladder cancer	5.74e-05	0.000167	CcSEcCtD
Riluzole—Headache—Epirubicin—urinary bladder cancer	5.71e-05	0.000166	CcSEcCtD
Riluzole—CYP1A1—Metabolism—PRSS3—urinary bladder cancer	5.68e-05	0.00072	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—SRC—urinary bladder cancer	5.62e-05	0.000712	CbGpPWpGaD
Riluzole—Dizziness—Doxorubicin—urinary bladder cancer	5.58e-05	0.000162	CcSEcCtD
Riluzole—SCN5A—Axon guidance—HRAS—urinary bladder cancer	5.54e-05	0.000702	CbGpPWpGaD
Riluzole—Nausea—Epirubicin—urinary bladder cancer	5.41e-05	0.000157	CcSEcCtD
Riluzole—Vomiting—Doxorubicin—urinary bladder cancer	5.36e-05	0.000156	CcSEcCtD
Riluzole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	5.36e-05	0.000679	CbGpPWpGaD
Riluzole—Rash—Doxorubicin—urinary bladder cancer	5.32e-05	0.000155	CcSEcCtD
Riluzole—Dermatitis—Doxorubicin—urinary bladder cancer	5.31e-05	0.000154	CcSEcCtD
Riluzole—Headache—Doxorubicin—urinary bladder cancer	5.28e-05	0.000154	CcSEcCtD
Riluzole—ABCG2—Metabolism—RRM2—urinary bladder cancer	5.23e-05	0.000664	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	5.04e-05	0.000639	CbGpPWpGaD
Riluzole—Nausea—Doxorubicin—urinary bladder cancer	5.01e-05	0.000146	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—EGFR—urinary bladder cancer	4.92e-05	0.000624	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—ENO2—urinary bladder cancer	4.85e-05	0.000615	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—HPGDS—urinary bladder cancer	4.85e-05	0.000615	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	4.78e-05	0.000606	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—NAT1—urinary bladder cancer	4.78e-05	0.000606	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GSTT1—urinary bladder cancer	4.7e-05	0.000596	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.7e-05	0.000596	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—TNF—urinary bladder cancer	4.69e-05	0.000594	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—KRAS—urinary bladder cancer	4.65e-05	0.00059	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.55e-05	0.000577	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—TYMP—urinary bladder cancer	4.54e-05	0.000575	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.4e-05	0.000558	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	4.37e-05	0.000554	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.36e-05	0.000553	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—NAT2—urinary bladder cancer	4.1e-05	0.00052	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—HRAS—urinary bladder cancer	3.95e-05	0.000501	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	3.93e-05	0.000499	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—NQO1—urinary bladder cancer	3.91e-05	0.000495	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	3.71e-05	0.000471	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	3.62e-05	0.000459	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—RRM2—urinary bladder cancer	3.54e-05	0.000449	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—ENO2—urinary bladder cancer	3.28e-05	0.000416	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—HPGDS—urinary bladder cancer	3.28e-05	0.000416	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.26e-05	0.000414	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GSTP1—urinary bladder cancer	3.26e-05	0.000413	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GSTT1—urinary bladder cancer	3.18e-05	0.000403	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.13e-05	0.000397	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—TYMS—urinary bladder cancer	3.03e-05	0.000384	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GSTM1—urinary bladder cancer	2.99e-05	0.00038	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—NCOR1—urinary bladder cancer	2.99e-05	0.00038	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.9e-05	0.000368	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—TYMP—urinary bladder cancer	2.89e-05	0.000367	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GPX1—urinary bladder cancer	2.87e-05	0.000364	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—ERCC2—urinary bladder cancer	2.81e-05	0.000357	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.78e-05	0.000352	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—MTHFR—urinary bladder cancer	2.65e-05	0.000336	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—NQO1—urinary bladder cancer	2.64e-05	0.000335	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—NAT2—urinary bladder cancer	2.62e-05	0.000332	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.57e-05	0.000325	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—RRM2—urinary bladder cancer	2.26e-05	0.000286	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.24e-05	0.000284	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	2.21e-05	0.00028	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PPARG—urinary bladder cancer	2.15e-05	0.000272	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.13e-05	0.000271	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	2.09e-05	0.000265	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—ENO2—urinary bladder cancer	2.09e-05	0.000265	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.08e-05	0.000264	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CREBBP—urinary bladder cancer	2.06e-05	0.000261	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—TYMS—urinary bladder cancer	2.05e-05	0.00026	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	2.03e-05	0.000257	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	2.03e-05	0.000257	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	2.03e-05	0.000257	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2e-05	0.000253	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GPX1—urinary bladder cancer	1.94e-05	0.000246	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	1.91e-05	0.000242	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	1.79e-05	0.000227	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.69e-05	0.000214	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.69e-05	0.000214	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.64e-05	0.000207	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.47e-05	0.000187	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PPARG—urinary bladder cancer	1.45e-05	0.000184	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.43e-05	0.000181	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.41e-05	0.000178	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—EP300—urinary bladder cancer	1.4e-05	0.000178	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	1.4e-05	0.000177	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.36e-05	0.000173	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.31e-05	0.000166	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.29e-05	0.000164	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.29e-05	0.000164	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.24e-05	0.000157	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.21e-05	0.000154	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	1.14e-05	0.000145	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.14e-05	0.000145	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PTEN—urinary bladder cancer	9.96e-06	0.000126	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—EP300—urinary bladder cancer	9.5e-06	0.000121	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PPARG—urinary bladder cancer	9.26e-06	0.000117	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	8.9e-06	0.000113	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	7.29e-06	9.24e-05	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PTEN—urinary bladder cancer	6.35e-06	8.06e-05	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—EP300—urinary bladder cancer	6.06e-06	7.68e-05	CbGpPWpGaD
